The genital form of the herpes virus infection is widespread and occurs in all population groups.The highest herpes incidence rate is recorded in people of the reproductive age, which significantly affects the maternal incidence, birth rate, perinatal losses, and nation’s health in general. Aim. The aim was to study the clinical efficacy of Valvir (generic valacyclovir produced by Actavis) in the therapy of the genital form of chronic recurrent herpes viral infection (CRHVI). Material and methods. In 2014, a comparative trial the clinical efficacy of Valvir in treatment of immunocompetent patients with the genital form of CRHVI was conducted at the clinic of the Iimunology Institute, Federal Medical and Biological Agency of Russia. Patients of the main group (20 males and females) were administered valacyclovir (Valvir), and patients of the control group (20 persons) were administered Acyclovir (produced in Russia). Results. On the background of five day Valvir therapy at the dose of 500 mg twice a day, the patients with the genital form of CRHVI demonstrated a reduction in the relapse duration (from 6.4 days before treatment to 3.8 days on treatment, on average), effective relief of the local relapse symptoms (up to 2.5±0.3 days), and a reduction in the period for the start of epitelization of herpetic lesions (up to 1.9 days) compared to the control group treated with Acyclovir. Conclusions. Valvir is a clinically proven effective medication for treating the genital form of CRHVI. A reduction in the duration of local relapse symptoms and the reepitelization period was demonstrated. Valvir was shown to be safe and well tolerated by both young and older patients.